News & Events
Macular Degeneration Clinical Trial
Published in OSN Retina, September 2012
Phase 1/2 prospective, randomized, double-blinded study of intravitreal anti-VEGF therapy combined with proton beam radiation versus sham irradiation in treating exudative age-related macular degeneration (PBAMD2)
UC Davis Eye Center
Author/Principal Investigator: Susanna S. Park, MD, PhD
The PBAMD2 study is a phase 1/2 study designed to further explore the safety and efficacy of low-dose proton beam irradiation combined with intravitreal anti-VEGF therapy — Lucentis (ranibizumab, Genentech) or Avastin (bevacizumab, Genentech) in treating eyes with newly diagnosed exudative age-related macular degeneration.
The RBSP was launched on August 23, 2012
Twin Probes to measure earth's radiation belt were launched August 23, 2012. Instruments were tested and calibrated at Crocker Nuclear Laboratory.
New Jungerman Hall honors Crocker Nuclear Laboratory's first director
One of the older buildings on central campus finally got an official name June 1 with the dedication of the building housing the Crocker Nuclear Laboratory as John A. Jungerman Hall.
Jungerman Hall was built to house the laboratory’s cyclotron—a type of particle accelerator—and opened in 1966. Jungerman, now professor emeritus of physics, was the laboratory’s founding director.
| Sunday | Monday | Tuesday | Wednesday | Thursday | Friday | Saturday |
|
|
|
|
1
|
2
|
3
|
4
|
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
|
31
|
